Related Experiment Video
Updated: Jun 4, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Interleukin-4 gene polymorphisms confer Behçet's disease in Turkish population
H B Oral1, K Dilek, A A Özçimen
1Department of Medical Microbiology, Immunology Unit, Uludag University Faculty of Medicine, Bursa, Turkey. oralb@uludag.edu.tr
Scandinavian Journal of Immunology
|February 18, 2011
Summary
Interleukin-4 (IL-4) gene promoter polymorphisms may increase Behçet
Area of Science:
- Immunogenetics
- Rheumatology
- Molecular Biology
Background:
- Cytokine gene polymorphisms influence individual susceptibility to diseases like Behçet's Disease (BD).
- Interleukin-4 (IL-4) and its receptor alpha (IL-4Rα) are key immune modulators.
- Understanding genetic associations can elucidate BD pathogenesis.
Purpose of the Study:
- To investigate the association between IL-4 and IL-4Rα gene polymorphisms and susceptibility to Behçet's Disease (BD) in a Turkish population.
- To explore the potential role of these polymorphisms in disease risk and clinical manifestations, such as Pathergy test positivity.
Main Methods:
- Genotyping of IL-4 and IL-4Rα gene polymorphisms was performed using Polymerase Chain Reaction (PCR) sequence-specific primers.
- DNA samples were analyzed from 97 BD patients and 76 healthy controls from a Turkish cohort.
- Allele and genotype frequencies were compared between patient and control groups.
Main Results:
- Higher frequencies of IL-4 gene promoter genotypes (-1098 TG and -590 CT) and alleles (-1098 G and -590 T) were observed in BD patients compared to controls.
- Specific IL-4 haplotypes (TTC) were found to be associated with BD.
- IL-4Rα gene polymorphism showed a potential association with Pathergy test positivity in BD patients.
Conclusions:
- IL-4 gene promoter polymorphisms may contribute to susceptibility to Behçet's Disease (BD).
- These genetic variations might increase the risk of developing BD.
- Further large-scale studies are required to confirm the association of IL-4 and IL-4Rα polymorphisms with BD.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...